Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Benzinga · 10/18 10:06
Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $23 price target.